Table 4. The changes of symptom scores and VUDS parameters in patients receiving the 1st external urethral sphincter placebo injection therapy followed by the 2nd injection therapy with onabotulinumtoxinA within dysfunctional voiding (DV) and detrusor underactivity (DU) patients.
| DV (N = 9) |
DU (N = 4) |
|||||
|---|---|---|---|---|---|---|
| Changes after the 1st injection | Changes after the 2nd injection | P value# | Changes after the 1st Injection | Changes after the 2nd injection | P value# | |
| IPSS-V | −6.1 ± 4.7* | −4.5 ± 7.1 | 0.585 | −7.0 ± 8.9 | −7.8 ± 8.7 | 0.908 |
| IPSS-S | −5.3 ± 4.4* | −2.9 ± 6.1 | 0.354 | −0.0 ± 3.6 | −2.3 ± 5.1 | 0.498 |
| IPSS-T | −11.4 ± 7.9* | −7.4 ± 12.1 | 0.419 | −7.0 ± 6.3 | −10.0 ± 4.5* | 0.468 |
| QoL-I | −2.3 ± 2.1* | −1.1 ± 2.5 | 0.289 | −1.75 ± 1.5 | −2.5 ± 2.1 | 0.580 |
| PPBC | −2.4 ± 2.1* | −1.6 ± 3.7 | 0.578 | −1.25 ± 1.0 | −2.5 ± 2.1 | 0.317 |
| CBC (mL) | −10.0 ± 245.7 | −29.6 ± 225.9 | 0.876 | −133.5 ± 336.7 | −88.5 ± 274.7 | 0.843 |
| Pdet (cmH2O) | −3.3 ± 14.1 | −8.7 ± 7.9* | 0.719 | 33.8 ± 47.0 | 10.8 ± 28.8 | 0.436 |
| Qmax (mL/s) | 1.0 ± 5.4 | 1.6 ± 4.5 | 0.800 | 3.8 ± 4.3 | 2.5 ± 4.1 | 0.691 |
| Vol. (mL) | 2.2 ± 123.6 | −5.0 ± 88.6 | 0.893 | 180.0 ± 260.6 | 69.5 ± 102.2 | 0.462 |
| PVR (mL) | −54.0 ± 201.7 | −107.6 ± 236.3 | 0.621 | −400.2 ± 309.2 | −251.3 ± 296.5 | 0.513 |
| VE (%) | 16.6 ± 27.3 | 15.5 ± 27.6 | 0.936 | 64.5 ± 38.9* | 22.3 ± 29.1 | 0.133 |
#p value between the changes of the parameters after the 1st and repeat injections.
*p value <0.05 versus baseline (or before the injection therapy).
IPSS, International Prostate Symptom Score; IPSS-V, IPSS voiding subscore; IPSS-S: IPSS storage subscore; IPSS-T, total IPSS score; PPBC, Patient Perception of Bladder Condition score; QoL-I, quality of life index; CBC, cystometric bladder capacity; Pdet, detrusor voiding pressure; Qmax, maximal urinary flow rate; Vol., voided volume; PVR, post-void residual; VE, voiding efficiency.
Data are expressed as mean ± standard deviation.